Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Toshiba American Medical Systems

This article was originally published in The Gray Sheet

Executive Summary

Formation of a new management team for the company's Ultrasound Business Unit has been completed, Toshiba states. Members of the management team include: T. Michael McLean, vice president, Ultrasound Business Unit, who was most recently vice president for Johnson & Johnson Clinical Diagnostics; Eli Wisner, director, Ultrasound Sales, who was previously general manager for Percusurge; and Ross Heaton, director, Ultrasound Marketing, who was senior vice president of marketing and sales for Perception Ultrasound International. The company says formation of this team "comes at a particularly important time as Toshiba launches its PowerVision 6000 system." Toshiba launched the PowerVision 6000 May 19 at the Leading Edge conference in Atlantic City, New Jersey. The mobile, 256-channel digital system offers high-end capabilities at a mid-range price, the firm claims...

You may also be interested in...

Specialists Advocate Helmet Ventilation For COVID-19 Hospital Treatment

Experts from the University of Chicago are advocating for helmet ventilation for COVID-19 patients. Medtech Insight spoke to acute nurse practitioner Aurika Savickaite who is helping lead an initiative to educate and raise awareness of the technology.


Global Medtech Guidance Tracker: March 2020

Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Sixty-nine guidance documents have been posted on the tracker since its last update.

AbbVie Brings In Non-EU Kaletra To Bolster Dwindling French Supplies

The US company is bringing extra supplies of lopinavir/ritonavir into France but stresses that the combination treatment is not authorized for treating patients with the coronavirus.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts